Luis C. Pena - 05 Nov 2025 Form 3 Insider Report for Evommune, Inc. (EVMN)

Role
President & CEO, Director
Signature
/s/ Gregory S. Moss, Attorney-in-Fact
Issuer symbol
EVMN
Transactions as of
05 Nov 2025
Transactions value $
$0
Form type
3
Filing time
05 Nov 2025, 20:10:05 UTC
Next filing
12 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Pena Luis C. President & CEO, Director C/O EVOMMUNE, INC., 1841 PAGE MILL ROAD, SUITE 100, PALO ALTO /s/ Gregory S. Moss, Attorney-in-Fact 05 Nov 2025 0001620548

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding EVMN Common Stock 659K 05 Nov 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding EVMN Series Seed Preferred Stock 05 Nov 2025 Common Stock 24.2K Direct F2
holding EVMN Employee Stock Option (Right to Buy) 05 Nov 2025 Common Stock 395K $3.07 Direct F3
holding EVMN Employee Stock Option (Right to Buy) 05 Nov 2025 Common Stock 103K $3.58 Direct F4
holding EVMN Employee Stock Option (Right to Buy) 05 Nov 2025 Common Stock 192K $3.84 Direct F5
holding EVMN Employee Stock Option (Right to Buy) 05 Nov 2025 Common Stock 23.8K $1.71 Direct F6
holding EVMN Employee Stock Option (Right to Buy) 05 Nov 2025 Common Stock 291K $2.99 Direct F7
holding EVMN Employee Stock Appreciation Right 05 Nov 2025 Common Stock 445K $2.99 Direct F8, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 189,003 restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. One fourth (1/4) of the RSUs shall vest on each of December 9, 2025, December 9, 2026, December 9, 2027 and December 9, 2028, subject to the Reporting Person's continuous service through each such vesting date.
F2 The Series Seed Preferred Stock is convertible into Common Stock on a 1-for-8.518 basis and has no expiration date. Upon the closing of the Issuer's initial public offering, all shares of Series Seed Preferred Stock will be converted into shares of Common Stock of the Issuer.
F3 One fourth (1/4) of the shares subject to the option award vested on May 11, 2023 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F4 One fourth (1/4) of the shares subject to the option award vested on January 13, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F5 One fourth (1/4) of the shares subject to the option award vested on May 12, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F6 One fourth (1/4) of the shares subject to the option award vested on January 6, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F7 One fourth (1/4) of the shares subject to the option award shall vest on December 9, 2025 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F8 Each Employee Stock Appreciation Right ("SAR") represents the contingent right to receive one share of common stock of the Issuer. The SARs vest upon: (i) a liquidity event requirement, which will be satisfied upon the first to occur of: (a) a Change in Control (as defined in the applicable SAR award agreement) or (b) upon completion of the Issuers initial public offering, at such time as the 30-day volume-weighted average price of the Issuer's common stock is greater than $40.75 and (ii) one fourth (1/4) of the SARs shall vest on each of December 9, 2025, December 9, 2026, December 9, 2027 and December 9, 2028, subject to the Reporting Person's continuous service through each such vesting date.
F9 The SARs have no expiration date.